InDex CEO Peter Zerouni presented an overview of how the company sees the way forward towards phase III based on the successful phase IIb study CONDUCT with the drug candidate cobitolimod. The presentation concluded with a Q&A session together with InDex Pharmaceuticals Chairman of the Board Wenche Rolfsen and Board Member Lennart Hansson.